These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 11005270)

  • 1. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
    Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
    J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.
    Palermo M; Delitala G; Mantero F; Stewart PM; Shackleton CH
    J Endocrinol Invest; 2001 Jan; 24(1):17-23. PubMed ID: 11227727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.
    Palermo M; Shackleton CH; Mantero F; Stewart PM
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):605-11. PubMed ID: 8977758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 11βHSD type 2 enzyme activity in essential hypertension and children with chronic kidney disease (CKD).
    Mongia A; Vecker R; George M; Pandey A; Tawadrous H; Schoeneman M; Muneyyirci-Delale O; Nacharaju V; Ten S; Bhangoo A
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3622-9. PubMed ID: 22872687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.
    Gelding SV; Taylor NF; Wood PJ; Noonan K; Weaver JU; Wood DF; Monson JP
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):153-62. PubMed ID: 9579226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
    Quinkler M; Zehnder D; Lepenies J; Petrelli MD; Moore JS; Hughes SV; Cockwell P; Hewison M; Stewart PM
    Eur J Endocrinol; 2005 Aug; 153(2):291-9. PubMed ID: 16061836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of deuterium-labeled cortisol for in vivo evaluation of renal 11beta-HSD activity in man: urinary excretion of cortisol, cortisone and their A-ring reduced metabolites.
    Kasuya Y; Shibasaki H; Furuta T
    Steroids; 2000 Feb; 65(2):89-97. PubMed ID: 10639020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11beta-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade.
    Kerstens MN; Buter H; Navis GJ; Dullaart RP
    Eur J Clin Invest; 2002 Jul; 32(7):513-8. PubMed ID: 12153552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
    Stewart PM; Corrie JE; Shackleton CH; Edwards CR
    J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric renal allograft transplantation does not normalize the increased cortisol/cortisone ratios of chronic renal failure.
    Schroth M; Plank C; Rauh M; Dörr HG; Rascher W; Dötsch J
    Eur J Endocrinol; 2006 Apr; 154(4):555-61. PubMed ID: 16556718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
    Finken MJ; Andrews RC; Andrew R; Walker BR
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3316-21. PubMed ID: 10487705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
    Stewart PM
    Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
    Ferrari P; Lovati E; Frey FJ
    J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furosemide and 11beta-hydroxysteroid dehydrogenase activity, in man.
    Palermo M; Armanini D; Shackleton CH; Sorba G; Cossu M; Roitman E; Scaroni C; Delitala G
    Exp Clin Endocrinol Diabetes; 2002 Sep; 110(6):272-6. PubMed ID: 12373630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1.
    Heiniger CD; Kostadinova RM; Rochat MK; Serra A; Ferrari P; Dick B; Frey BM; Frey FJ
    FASEB J; 2003 May; 17(8):917-9. PubMed ID: 12626438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
    Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary cortisol to cortisone metabolites in hypertensive obese children.
    Csábi GY; Juricskay S; Molnár D
    J Endocrinol Invest; 2000; 23(7):435-9. PubMed ID: 11005267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.
    Campino C; Carvajal CA; Cornejo J; San Martín B; Olivieri O; Guidi G; Faccini G; Pasini F; Sateler J; Baudrand R; Mosso L; Owen GI; Kalergis AM; Padilla O; Fardella CE
    Endocrine; 2010 Feb; 37(1):106-14. PubMed ID: 19882252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent mineralocorticoid excess syndromes.
    Shimojo M; Stewart PM
    J Endocrinol Invest; 1995; 18(7):518-32. PubMed ID: 9221270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.